Connection

Giordano Madeddu to Piperazines

Back to Details
This is a "connection" page, showing publications Giordano Madeddu has written about Piperazines.
Giordano Madeddu
Connection Strength
0.102
Piperazines
  1. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018 07 31; 18(1):357.
    View in: PubMed
    Score: 0.036
  2. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS. 2017 01 28; 31(3):455-457.
    View in: PubMed
    Score: 0.033
  3. Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017 01 28; 31(3):457-459.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.